MedTrace Logo

Iparomlimab and Tuvonralimab Injection for Untreated Locally Advanced Nasopharyngeal Carcinoma

NCT07135804 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2025-08-22

No results posted yet for this study

Summary

This is a prospective, multicenter phase II clinical study. The subjects are patients with previously untreated locally advanced nasopharyngeal carcinoma, with clinical staging of IVA, T1-4, N3, M0. The study aims to preliminarily evaluate the efficacy and safety of Iparomlimab and Tuvonralimab Injectionin the treatment of these patients.

Conditions

  • Locally Advanced Nasopharyngeal Squamous Cell Carcinoma

Interventions

DRUG

Iparomlimab and Tuvonralimab Injection

Patients will receive Iparomlimab and Tuvonralimab Injection on the basis of 3 cycles of induction chemotherapy, followed by standard concurrent chemoradiotherapy, and then 9 cycles of Iparomlimab and Tuvonralimab Injection as adjuvant therapy

Sponsors & Collaborators

  • Second Affiliated Hospital of Nanchang University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-01
Primary Completion
2028-04-30
Completion
2031-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07135804 on ClinicalTrials.gov